A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 4,800 shares of PDSB stock, worth $17,808. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,800
Previous 10,900 55.96%
Holding current value
$17,808
Previous $43,000 67.44%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.55 - $4.02 $6,770 - $10,673
-2,655 Reduced 5.17%
48,710 $142,000
Q1 2024

May 15, 2024

SELL
$3.85 - $6.59 $304,215 - $520,722
-79,017 Reduced 60.6%
51,365 $203,000
Q4 2023

Feb 14, 2024

BUY
$3.95 - $6.58 $135,852 - $226,305
34,393 Added 35.83%
130,382 $647,000
Q3 2023

Nov 14, 2023

BUY
$4.8 - $6.4 $216,662 - $288,883
45,138 Added 88.77%
95,989 $484,000
Q2 2023

Aug 14, 2023

SELL
$5.03 - $9.9 $372,501 - $733,154
-74,056 Reduced 59.29%
50,851 $255,000
Q1 2023

May 15, 2023

BUY
$5.68 - $11.99 $554,816 - $1.17 Million
97,679 Added 358.74%
124,907 $768,000
Q4 2022

Feb 14, 2023

SELL
$3.28 - $13.2 $301,087 - $1.21 Million
-91,795 Reduced 77.12%
27,228 $359,000
Q3 2022

Nov 14, 2022

BUY
$2.97 - $5.79 $258,704 - $504,343
87,106 Added 272.91%
119,023 $353,000

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $106M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.